Bill 118 hr 6021, also known as the Ejiao Act of 2023, is a piece of legislation currently being considered by the US Congress. The bill aims to regulate the import and sale of ejiao, a traditional Chinese medicine made from the gelatin of donkey hides.
The bill seeks to address concerns about the cruelty and sustainability of the donkey skin trade, as well as the potential health risks associated with the consumption of ejiao. If passed, the Ejiao Act of 2023 would require all ejiao products sold in the US to be sourced from donkeys that have been raised and slaughtered in a humane manner, and to meet certain quality and safety standards.
Additionally, the bill would impose restrictions on the importation of ejiao products from countries that do not meet these standards, in an effort to protect consumers and promote ethical practices in the donkey skin trade.
Overall, the Ejiao Act of 2023 represents an important step towards regulating the ejiao industry and ensuring the welfare of donkeys, while also safeguarding the health and safety of consumers.